Literature DB >> 12776184

Human arteries engineered in vitro.

J Andrew McKee1, Soma S R Banik, Matthew J Boyer, Nesrin M Hamad, Jeffrey H Lawson, Laura E Niklason, Christopher M Counter.   

Abstract

There is a pressing need to develop methods to engineer small-calibre arteries for bypass surgery. We hypothesized that the rate-limiting step that has thwarted previous attempts to engineer such vessels from non-neonatal tissues is the limited proliferative capacity of smooth muscle cells (SMCs), which are the main cellular component of these vessels. Ectopic expression of the human telomerase reverse transcriptase subunit (hTERT) has been shown recently to extend the lifespan of certain human cells. We therefore introduced hTERT into human SMCs and found that the resulting cells proliferated far beyond their normal lifespan but retained characteristics of normal control SMCs. Importantly, using these non-neonatal SMCs, we were able to engineer mechanically robust human vessels, a crucial step towards creating arteries of clinical value for bypass surgery.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12776184      PMCID: PMC1319197          DOI: 10.1038/sj.embor.embor847

Source DB:  PubMed          Journal:  EMBO Rep        ISSN: 1469-221X            Impact factor:   8.807


  40 in total

Review 1.  Can ends justify the means?: telomeres and the mechanisms of replicative senescence and immortalization in mammalian cells.

Authors:  J M Sedivy
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

Review 2.  Reversing time: origin of telomerase.

Authors:  T M Nakamura; T R Cech
Journal:  Cell       Date:  1998-03-06       Impact factor: 41.582

3.  Extension of life-span by introduction of telomerase into normal human cells.

Authors:  A G Bodnar; M Ouellette; M Frolkis; S E Holt; C P Chiu; G B Morin; C B Harley; J W Shay; S Lichtsteiner; W E Wright
Journal:  Science       Date:  1998-01-16       Impact factor: 47.728

4.  Advances in quantification and characterization of telomerase activity by the telomeric repeat amplification protocol (TRAP).

Authors:  N W Kim; F Wu
Journal:  Nucleic Acids Res       Date:  1997-07-01       Impact factor: 16.971

Review 5.  A survey of telomerase activity in human cancer.

Authors:  J W Shay; S Bacchetti
Journal:  Eur J Cancer       Date:  1997-04       Impact factor: 9.162

Review 6.  Telomerase, cell immortality, and cancer.

Authors:  C B Harley; N W Kim; K R Prowse; S L Weinrich; K S Hirsch; M D West; S Bacchetti; H W Hirte; C M Counter; C W Greider
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1994

Review 7.  Regulation of differentiation of vascular smooth muscle cells.

Authors:  G K Owens
Journal:  Physiol Rev       Date:  1995-07       Impact factor: 37.312

8.  hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization.

Authors:  M Meyerson; C M Counter; E N Eaton; L W Ellisen; P Steiner; S D Caddle; L Ziaugra; R L Beijersbergen; M J Davidoff; Q Liu; S Bacchetti; D A Haber; R A Weinberg
Journal:  Cell       Date:  1997-08-22       Impact factor: 41.582

9.  A completely biological tissue-engineered human blood vessel.

Authors:  N L'Heureux; S Pâquet; R Labbé; L Germain; F A Auger
Journal:  FASEB J       Date:  1998-01       Impact factor: 5.191

10.  Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span.

Authors:  H Vaziri; S Benchimol
Journal:  Curr Biol       Date:  1998-02-26       Impact factor: 10.834

View more
  45 in total

1.  Hair follicle-derived smooth muscle cells and small intestinal submucosa for engineering mechanically robust and vasoreactive vascular media.

Authors:  Hao-Fan Peng; Jin Yu Liu; Stelios T Andreadis; Daniel D Swartz
Journal:  Tissue Eng Part A       Date:  2011-01-16       Impact factor: 3.845

2.  A new approach to making autoprostheses for angioplasty.

Authors:  V A Chereshnev; B G Yushkov; N V Tyumentseva; S Yu Medvedeva; V V Khodakov; D I Krokhin; K V Mersaidov
Journal:  Dokl Biol Sci       Date:  2006 May-Jun

3.  Fibroblast growth factor 9 delivery during angiogenesis produces durable, vasoresponsive microvessels wrapped by smooth muscle cells.

Authors:  Matthew J Frontini; Zengxuan Nong; Robert Gros; Maria Drangova; Caroline O'Neil; Mona N Rahman; Oula Akawi; Hao Yin; Christopher G Ellis; J Geoffrey Pickering
Journal:  Nat Biotechnol       Date:  2011-04-17       Impact factor: 54.908

Review 4.  Development of small-diameter vascular grafts.

Authors:  Xinwen Wang; Peter Lin; Qizhi Yao; Changyi Chen
Journal:  World J Surg       Date:  2007-04       Impact factor: 3.352

Review 5.  Achieving the ideal properties for vascular bypass grafts using a tissue engineered approach: a review.

Authors:  Sandip Sarkar; Thomas Schmitz-Rixen; George Hamilton; Alexander M Seifalian
Journal:  Med Biol Eng Comput       Date:  2007-03-06       Impact factor: 2.602

6.  Molecular and functional effects of organismal ageing on smooth muscle cells derived from bone marrow mesenchymal stem cells.

Authors:  Juhee Han; Jin Yu Liu; Daniel D Swartz; Stelios T Andreadis
Journal:  Cardiovasc Res       Date:  2010-01-22       Impact factor: 10.787

Review 7.  [Tissue engineering of vascular prostheses].

Authors:  B H Walpoth; M Möller
Journal:  Chirurg       Date:  2011-04       Impact factor: 0.955

8.  Angiotensin II-mediated oxidative DNA damage accelerates cellular senescence in cultured human vascular smooth muscle cells via telomere-dependent and independent pathways.

Authors:  Karl E Herbert; Yogita Mistry; Richard Hastings; Toryn Poolman; Laura Niklason; Bryan Williams
Journal:  Circ Res       Date:  2007-11-08       Impact factor: 17.367

Review 9.  Biomaterials for vascular tissue engineering.

Authors:  Swathi Ravi; Elliot L Chaikof
Journal:  Regen Med       Date:  2010-01       Impact factor: 3.806

10.  Differentiation of bone marrow mesenchymal stem cells into the smooth muscle lineage by blocking ERK/MAPK signaling pathway.

Authors:  Kenichi Tamama; Chandan K Sen; Alan Wells
Journal:  Stem Cells Dev       Date:  2008-10       Impact factor: 3.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.